ATHE · Alterity Therapeutics Limited

Alterity Therapeutics reported a cash balance of A$44.53 million as of March 31, 2026, with operating cash outflows of A$4.73 million for the quarter. The company achieved significant regulatory milestones, receiving positive feedback from two FDA Type C meetings supporting key elements of its planned Phase 3 program for ATH434 in Multiple System Atrophy (MSA), including clinical pharmacology, non-clinical development, and CMC. The End-of-Phase 2 meeting with the FDA remains on track for mid-2026. New Phase 2 data presented at the AAN annual meeting demonstrated that ATH434 slowed disease progression on the novel MuSyCA composite endpoint, with a treatment effect of up to 41% relative to placebo at Week 52. The company strengthened its leadership by appointing Dr. Daniel Claassen as Chief Medical Advisor and Ms. Ann Cunningham to the Board. Alterity continues to engage with pharmaceutical companies regarding potential strategic collaboration opportunities for ATH434. The strong cash position provides a solid runway to advance regulatory, clinical, and commercial objectives.